These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29610401)

  • 21. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
    Montalban C; Montellano MB; Santos J; Lavis N
    Hum Vaccin Immunother; 2018 Mar; 14(3):593-595. PubMed ID: 28933626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm study.
    Chang CY; Cho CY; Lai CC; Lu CY; Chang LY; Hung MC; Huang LM; Wu KG
    Vaccine; 2020 May; 38(22):3839-3846. PubMed ID: 32284272
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA; Claeys C; Aranza Doniz C; Feng Y; Innis BL; Jain VK; Peeters M
    Pediatr Infect Dis J; 2014 Dec; 33(12):1262-9. PubMed ID: 25386965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.
    Brady RC; Hu W; Houchin VG; Eder FS; Jackson KC; Hartel GF; Sawlwin DC; Albano FR; Greenberg M
    Vaccine; 2014 Dec; 32(52):7141-7. PubMed ID: 25454878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
    Huang C; Fu X; Zhou Y; Mi F; Tian G; Liu X; Wu J; Ding C; Yan D; Li L; Yang S
    Vaccine; 2020 Feb; 38(6):1332-1344. PubMed ID: 31948819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
    Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of zoster vaccine live administered with quadrivalent influenza virus vaccine.
    Levin MJ; Buchwald UK; Gardner J; Martin J; Stek JE; Brown E; Popmihajlov Z
    Vaccine; 2018 Jan; 36(1):179-185. PubMed ID: 28830693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials.
    Moa AM; Chughtai AA; Muscatello DJ; Turner RM; MacIntyre CR
    Vaccine; 2016 Jul; 34(35):4092-4102. PubMed ID: 27381642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial.
    Dawood FS; Naleway AL; Flannery B; Levine MZ; Murthy K; Sambhara S; Gangappa S; Edwards L; Ball S; Grant L; Belongia E; Bounds K; Cao W; Gross FL; Groom H; Fry AM; Rentz Hunt D; Jeddy Z; Mishina M; Kim SS; Wesley MG; Spencer S; Thompson MG; Gaglani M
    Clin Infect Dis; 2021 Dec; 73(11):1973-1981. PubMed ID: 34245243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
    J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial.
    Langley JM; Wang L; Aggarwal N; Bueso A; Chandrasekaran V; Cousin L; Halperin SA; Li P; Liu A; McNeil S; Mendez LP; Rivera L; Innis BL; Jain VK
    J Pediatric Infect Dis Soc; 2015 Sep; 4(3):242-51. PubMed ID: 26336604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of the first indigenously developed Indian tetravalent influenza vaccine (split virion) in healthy adults ≥ 18 years of age: A randomized, multicenter, phase II / III clinical trial.
    Sharma S; Singh VB; Kumar S; Prajapati V; Patel J; Vukkala R; Jangid SK; Sanmukhani J; Gupta G; Patel P; Mittal R; Glueck R
    Hum Vaccin Immunother; 2018 Jun; 14(6):1362-1369. PubMed ID: 29461913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial.
    Jamshed S; Walsh EE; Dimitroff LJ; Santelli JS; Falsey AR
    Vaccine; 2016 Jan; 34(5):630-635. PubMed ID: 26721330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study.
    Fan R; Huang X; Nian X; Ou Z; Zhou J; Zhang J; Zeng P; Zhao W; Deng J; Chen W; Chen S; Duan K; Chen Y; Li X; Zhang J; Yang X
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-9. PubMed ID: 34473607
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
    Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults.
    Gorse GJ; Falsey AR; Ozol-Godfrey A; Landolfi V; Tsang PH
    Vaccine; 2015 Feb; 33(9):1151-9. PubMed ID: 25613721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.